NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

GENETIC TECHNOLOGIES LIMITED (GTG)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 FROMTO
GENETIC TECHNOLOGIES LIMITED04/09/2000
DUKETON GOLDFIELDS LIMITED01/11/199904/09/2000
DUKETON GOLDFIELDS NL20/03/199501/11/1999
CONSOLIDATED VICTORIAN MINES NL20/02/199220/03/1995
CONSOLIDATED VICTORIAN GOLD MINES NL22/08/199120/02/1992
CONCORD MINING NL22/08/1991

Shareholder links

Our website ranking of GTG: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Computershare Melbourne
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000GTG7
Address: Suite 7, Level 1, 321 Chapel Street PRAHRAN VIC 3181
Tel:  (03) 8412 7000Fax: (03) 8412 7040

Date first listed: 30/07/1987

Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Biotechnology company, pursuing commercial opportunities in the out-licensing of its non-coding patents globally, expanding its genetic service-testing business in the Asia-Pacific Region and supporting certain research projects

News & Events

Expand this box to read and print

The company's Voluntary Administrators have called a reconvened second creditors' meeting on 12 February 2025. The meeting will decide whether to execute a DOCA, end administration, or wind up the company. The Administrators believe it is in creditors' interests.

05/02/2025

The entities suspended for over three months failed periodic reports, the oldest outstanding report deadline, and their 2 year deadline for trading plans. If not met, they will be removed from the official list, usually after the first trading day.

22/01/2025

On 15 January 2025, Genetic Technologies Limited entered into a conditional agreement to sell its direct to consumer AffinityDNA and EasyDNA businesses to Endeavor DNA, Inc. On Saturday, 18 January 2025 the sale of the AffinityDNA and EasyDNA businesses completed. GTG has also granted Endeavor an option to purchase two of its subsidiaries that employ persons involved in conducting the businesses, exercisable by Endeavor within four weeks following completion. As the transaction has completed, Endeavor DNA, Inc. will operate the businesses on and from Saturday, 18 January 2025.

20/01/2025

The company is set to sell its Direct-to-Consumer businesses and assets, including brands like EasyDNA, AffinityDNA, GTLDNA, HomeDNADirect, and International Biosciences, through an Asset Sale Agreement.

15/01/2025

The company has completed the sale of its geneTypeTM business and assets to Rhythm Biosciences Limited, ensuring a smooth transition and satisfaction of conditions precedent.

24/12/2024

Rhythm Biosciences Ltd has entered into an Asset Sale Agreement with Genetic Technologies Ltd for the acquisition of select assets related to the Genetype business.

23/12/2024

The Administrators issued a Report to Creditors on 13 December 2024, announcing the second meeting of creditors for the Company. The meeting is scheduled for 20 December 2024 via videoconference and will be adjourned for up to 45 business days. The Administrators aim to reconvene the meeting earlier than 45 days and provide creditors with 5 business days' notice.

13/12/2024

The company has received a Delisting Notice from Nasdaq Stock Market LLC due to the appointment of Voluntary Administrators. The company's American Depository Shares will be suspended from trading on 17 December 2024, and a Form 25-NSE will be filed with the SEC. Nasdaq cited public interest concerns, residual equity interest, and compliance with Nasdaq Listing Rule 5550(b).

13/12/2024

The company plans to rely on the ASIC Corporations Instrument 2015/251, which allows for the deferral of financial reporting obligations for a minimum of 6 months and up to a maximum of 24 months. During the deferral period, GTG is not required to comply with any obligations under Part 2M.3 of the Corporations Act, and its Annual General Meeting is deferred until at least 2 months after the financial reporting relief ceases.

02/12/2024

The company lodges a response to an ASX Query.

29/11/2024

The Company offered shareholders a 2 for 3 rights issue to raise $2 million to $3.88 million, intended for working capital and operational transition. Administrators approved the withdrawal of the Offer, closing all offers, avoiding securities issues, and refunding all funds.

26/11/2024

The company's securities were suspended on October 21, 2024, pending an announcement about an entitlement offer and strategic distribution partnership. Following the appointment of voluntary administrators, the suspension will continue until ASX confirms compliance with Listing Rules.

22/11/2024

Ross Blakeley and Paul Harlond were appointed as Joint and Several Voluntary Administrators effective 20 November 2024.

20/11/2024

The company has extended the closing date of all offers under the Entitlement Offer Prospectus to 2 December 2024. The company also extended the voluntary suspension of its securities until the commencement of trade or an earlier market announcement. The suspension is necessary for finalizing funding, securing distribution partnerships, investment, and minimum orders.

01/11/2024

The company releases its Quarterly Activities/Appendix 4C Cash Flow Report.

31/10/2024

The company has extended its voluntary suspension of its securities until the commencement of trade on 4 November 2024. The suspension was granted due to the need for additional time to finalize agreements, secure funding, and secure distribution partnerships.

24/10/2024

The securities of Genetic Technologies Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GTG, pending the release of an announcement regarding an entitlement offer and a strategic distribution partnership.

21/10/2024

The following ordinary fully paid deferred shares of Genetic Technologies Limited will be suspended from quotation immediately under Listing Rule 17.3, due to the minimum subscription condition under the Non-Renounceable Entitlement Offer not having been meet: Security class code GTGN.

16/09/2024

The suspension of trading in the securities of Genetic Technologies Limited will be lifted immediately, following the release by GTG of an announcement regarding a breach of Chapter 10 of the Listing Rules.

06/08/2019

The company provides an operational update on its blockchain activities. In relation to the framework agreement between BCG and GTG, to date, no shares have been issued under the framework agreement and no milestones specified have been achiebed. The share price of GTG needs to reach and remain at a minimum of 2.5c prior to any milestone shares being issued. Any rights to the 486,000,000 milestone shares upon achievement of milestones lapse between 27 December 2019 and 27 June 2020. Also, the Blockshine Health joint venture agreement was terminated on 6 August 2019. Regarding project Shivom which was signed on 2 March 2018, the parties have not progressed further with the undertakings contained in the agreement in recent times. GTG is yet to receive any formal requests for resources or further input or consideration into any blockchain based projects, whether that be via the previous Blockshine Health Joint Venture, BCG or from any other party. As such, GTG intends to remain focused on its core genetic testing business activities and are not currently considering any blockchain related projects. There is no present intention of the Board to change its composition.

06/08/2019

ASX suspended the company for breach of Listing 10.1 and required the company to take corrective action. One form of corrective action was to cancel the transaction. The JV agreement has been terminated effective 6 August 2019. GTG did not receive any formal requests for resources or further input or consideration into any blockchain based projects via the Blockshine Health Joint Venture. As such, GTG has been very focused on its core genetic testing business activities this past calendar year and considers termination of the JV agreement will have no material adverse impact on company operations.

06/08/2019

The securities of Genetic Technologies Limited will be suspended from quotation immediately under Listing Rule 17.3, pending an announcement regarding a breach of Chapter 10 of the Listing Rules.

02/08/2019

The securities of Genetic Technologies Limited will be reinstated to quotation immediately, following the release of an announcement by the Company.

15/02/2018

The company has entered into a non-binding terms sheet with Blockchain Global. In addition, in order to secure additional working capital, the Company has also mandated Lodge Corporate Pty Ltd to assist in a proposed private placement of up to 324.7 million new GTG fully paid ordinary shares at an issue price of 0.014c per GTG share.

15/02/2018

The company is presently in discussions with ASX regarding the possible application of ASX Listing Rule 11.1; its structure / operations in compliance with ASX Listing Rule 12.5 and whether a strategic alliance with Blockchain Global Ltd to explore the application of Blockchain technology to provide efficiencies and new opportunities leveraging off the GTG existing genomics business would result in a change of activities of GTG. While these discussions are continuing, the ASX has required that GTG continue in suspension.

12/02/2018

The securities of Genetic Technologies Limited will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company.

31/01/2018

The suspension of trading in the securities of Genetic Technologies Limited will be lifted immediately following the release of an announcement regarding restructuring plans and finalisation of funding. ASX Code: GTG

15/09/2014

The securities of Genetic Technologies Limited (the "Company") will be suspended from quotation immediately at the request of the Company pending the release of an announcement. Security Code: GTG

11/09/2014

securities reinstated

22/07/2011

Genetic Technologies now expects that the capital raising will be finalised on 22 July 2011 (AEST), when a further announcement is expected to be made by the Company in compliance with the ASX listing rules, and at which time the Company expects to recommence trading on both the ASX and NASDAQ

20/07/2011

securities suspended pending an announcement

13/07/2011

Geoffrey Edgar Newing, 44, of Hawthorn East, Victoria, is sentenced to a total of 22 months imprisonment and was ordered to serve six months of this sentence before being released on a recognisance release order

18/03/2010

former Genetic Technologies Limited (GTG) chief operating officer, Geoffrey Edgar Newing, today pleaded guilty to five counts of market manipulation in the Melbourne Magistrates' Court, following an investigation by ASIC - the charges relate to Mr Newing's involvement in the trading of GTG shares between 16 May 2006 and 7 August 2006 - ASIC alleges that during this period Mr Newing took part in transactions involving purchases of more than 2,500,000 GTG shares through a share trading account held in the name of his related company, Palamine Pty Ltd. These transactions, according to ASIC, were likely to create or maintain an artificial price for trading in GTG shares

25/01/2010

name changed from Duketon Goldfields Limited

04/09/2000

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    06/03/2024Peter Rubenstein617,209$0.130$80,315
    30/01/2023Jerzy Muchnicki-38,400,000$0.873
    USD
    $33,539,328
    02/06/2020Lindsay Wakefield1,092,841$0.006$6,284
    02/06/2020Nick Burrows1,670,000$0.006$10,020
    29/05/2020Peter Rubenstein60,000,000$0.005$314,960

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Peter RubensteinChairman31/01/2018
    Simon MorrissCEO01/02/2021
    Mark ZiirsenCFO, Company Secretary16/07/2024
    Lindsay WakefieldNon Exec Director24/09/2014
    Jerzy MuchnickiExecutive Director31/01/2018

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Kathryn AndrewsCFO, Company Secretary25/03/202428/06/2024
    Tony Di PietroCFO10/10/202231/03/2024
    Nick BurrowsNon Exec Director02/09/201915/02/2024
    Michael TonroeCFO28/06/202130/11/2022
    Stan SackCOO18/05/202030/04/2022
    Phillip HainsCFO15/07/201915/06/2021
    Paul KasianChairman, CEO12/12/201324/09/2019
    Paul VineyCFO, COO27/12/201815/07/2019
    Sam LeeNon Exec Director31/01/201809/07/2019
    Kevin FisherCFO02/11/201531/12/2018
    Eutillio BuccilliDirector, CEO02/06/201406/02/2018
    Malcolm BrandonNon Exec Chairman05/10/200930/01/2018
    Grahame LeonardNon Exec Director29/11/201330/01/2018
    Susan GrossDirector20/06/201615/09/2017
    Brian ManuelCFO15/06/201502/11/2015
    David CarterNon Exec Director24/09/201429/01/2015
    Alison MewCEO31/08/200931/12/2014
    Ian McKenzieNon Exec Director29/11/201329/11/2014
    Mervyn CassNon Exec Director30/09/201127/11/2014
    Tom HowittCFO, Deputy CEO01/06/200428/03/2014
    Tom BonvinoNon Exec Director25/11/200929/11/2013
    Ben SilluzioNon Exec Director10/12/201229/11/2013
    Melvyn BridgesChairman, Non Exec Director16/12/201127/11/2012
    Paul MacLemanCEO04/05/200927/11/2012
    Gregory BrownNon Exec Director24/07/201227/11/2012
    Huw JonesDirector20/11/200827/11/2012
    Sidney HackNon Exec Director19/11/200818/12/2011
    Fred BartNon Exec Chairman25/10/199626/11/2009
    Mervyn JacobsonNon Exec Director15/05/202014/12/2008
    Henry BoschNon Exec Chairman24/06/200521/11/2008
    Michael OhanessianCEO24/09/200721/11/2008
    David CarruthersNon Exec Director26/02/200721/11/2008
    John DawkinsNon Exec Director24/11/200421/11/2008
    Leanne RoweNon Exec Director16/04/200821/11/2008
    Robert EdgeNon Exec Director19/04/200419/11/2006
    Ian DennisExecutive Director24/11/199426/11/2004
    Russell GranzowExecutive Director06/05/200321/04/2004
    Ian GustNon Exec Director26/04/200102/12/2001
    Peter VassilieffNon Exec Director28/04/2001

    Date of first appointment, title may have changed.